Vivos Therapeutics (VVOS) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for Vivos Therapeutics
Is Vivos Therapeutics a buy right now? The alternative data says hold. This VVOS stock analysis is built on the 25+ alternative data signals AltIndex tracks on Vivos Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 48/100: a Hold. The stock trades at $0.15 with a $3M market cap.
The data leans positive over the past 90 days — headcount (according to LinkedIn) up 7.8% to 83 employees, and sentiment up 136.8% to 90/100 — but the move hasn’t been broad enough to lift VVOS into buy territory yet.
VVOS’s broader alt-data profile also covers web traffic (14K monthly visits), and quarterly revenue ($10M). Every signal links to its own page with full history, the VVOS technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on VVOS is just below.
Vivos Therapeutics AI Stock Analysis
Vivos Therapeutics is a company focused on the development and commercialization of innovative treatments for sleep apnea and other airway-related disorders. They aim to offer non-invasive, patient-friendly solutions that help individuals manage these conditions effectively.
Analysis generated October 2, 2026.
Recent Vivos Therapeutics Stock Alerts
|
Vivos Therapeutics | September 29 Price is up by 6.7% in the last 24h. |
|
Vivos Therapeutics | September 28 Price is down by -6.8% in the last 24h. |
|
Vivos Therapeutics | September 23 Price is down by -9.3% in the last 24h. |
|
Vivos Therapeutics | September 10 Price is up by 6.5% in the last 24h. |
Vivos Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 14K | 4.9% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 83 | 7.8% | |
| Sentiment | 90 | 136.8% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 5 | 75.0% | |
| Stocktwits Mentions | 91 | 45.5% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 6K | 2.7% |
About Vivos Therapeutics (VVOS)
Vivos Therapeutics, Inc., a medical technology company, is dedicated to developing and commercializing treatment alternatives for patients with sleep-disordered breathing, such as mild to moderate obstructive sleep apnea (OSA). The company is headquartered in Highlands Ranch, Colorado.
| Price | $0.15 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $3M |
| Year Range | $0 – $3 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Medical Devices |
Latest Vivos Therapeutics News
View more →
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred EquityJune 22 - GlobeNewswire |
|
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights OfferingJune 11 - GlobeNewswire |
|
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular PatientsJune 10 - GlobeNewswire |
|
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026June 8 - GlobeNewswire |
|
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq ListingJune 5 - GlobeNewswire |
See Vivos Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for VVOS, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEVivos Therapeutics Earnings & Financial Performance
View all earnings →Vivos Therapeutics Insider Trading Activity
View all →| Skaff Michael C filed to sell 859,166 shares at $0.0. Jun 30 '26 |
| Skaff Michael C filed to sell 2,749,330 shares at $0.0. Jun 30 '26 |
| Skaff Michael C filed to sell 2,749,330 shares at $0.0. Jun 30 '26 |
| Skaff Michael C filed to sell 1,353,625 shares at $0.0. Mar 31 '26 |
| Skaff Michael C filed to sell 429,957 shares at $0.0. Mar 31 '26 |
Vivos Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Vivos Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Fresh2 GroupFRES |
$0.85 0.0% | $3M | 43 |
 |
Tenon MedicalTNON |
$3.70 0.0% | $2M | 46 |
 |
NuwellisNUWE |
$0.69 0.0% | $2M | 40 |
 |
Adagio Medical HoldingsADGM |
$0.14 7.8% | $4M | 44 |
 |
Trinity BiotechTRIB |
$5.77 1.4% | $5M | 40 |
Explore Vivos Therapeutics Data
Frequently Asked Questions: Vivos Therapeutics (VVOS)
Vivos Therapeutics has an AltIndex AI Score of 48/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
48/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Vivos Therapeutics (VVOS) stock is $0.15 with a market cap of $3M.
As of today, Vivos Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Vivos Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Vivos Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The VVOS stock price chart above shows Vivos Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Vivos Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Vivos Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
